You just read:

Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet

News provided by

Eisai Inc.

Feb 15, 2018, 08:08 ET